Calcium and the Failing Heart: Phospholamban, Good Guy or Bad Guy?

Sci. STKE, 29 April 2003
Vol. 2003, Issue 180, p. pe15
DOI: 10.1126/stke.2003.180.pe15

Calcium and the Failing Heart: Phospholamban, Good Guy or Bad Guy?

  1. Robert H. G. Schwinger1,* and
  2. Konrad F. Frank1
  1. 1Laboratory of Muscle Research and Molecular Cardiology, Department of Internal Medicine III, Joseph-Stelzmannstrasse, 50924 Köln, Germany.
  1. *Corresponding author. Robert H. G. Schwinger; telephone, +49 221 478 3138; fax, +49 221 478 3746; e-mail, robert.schwinger{at}medizin.uni-koeln.de

Abstract

In cardiac cells, phospholamban is a potent inhibitor of sarcoplasmic reticulum calcium (Ca2+) transport. Overexpression of mutant forms of phospholamban may result in beneficial or detrimental effects on intracellular Ca2+ handling and cardiac systolic and diastolic function. Mutations in phospholamban have also been linked to human cardiomyopathies, providing important insights into the underlying disease mechanisms and the key role of phospholamban in myocardial excitation-contraction coupling. This Perspective discusses new advances in our understanding of the role of phospholamban in intracellular Ca2+ handling and the development of human and murine cardiomyopathies.

Citation:

R. H. Schwinger and K. F. Frank, Calcium and the Failing Heart: Phospholamban, Good Guy or Bad Guy?. Sci. STKE 2003, pe15 (2003).

Localized Effects of cAMP Mediated by Distinct Routes of Protein Kinase A
K. TASKEN, and E. M. AANDAHL
Physiol. Rev. 84, 137-167 (1 January 2004)

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882